The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Market Value Trend Is Expected For The Non Hodgkin Lymphoma (NHL) Market From 2026 To 2030?
The non-Hodgkin lymphoma (NHL) market has witnessed substantial expansion in recent years. It is anticipated to increase from $10.86 billion in 2025 to $11.73 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.0%. This historical growth can be linked to factors like the rising global occurrence of NHL, advancements in chemotherapy protocols, increased healthcare spending, heightened awareness of lymphatic cancers, and the growth of oncology hospital infrastructure.
The non-Hodgkin lymphoma (NHL) market is poised for significant expansion in the coming years. Its valuation is projected to reach $16.44 billion by 2030, driven by a compound annual growth rate (CAGR) of 8.8%. This anticipated growth during the forecast period is primarily attributed to factors such as the expanding pipeline of targeted therapies, an increase in biologic approvals, the growing uptake of personalized medicine, broader market access in developing regions, and the rise in stem cell transplant procedures. Key trends shaping the market during this period include a greater embrace of immunotherapy and targeted therapies, more frequent application of combination treatment regimens, an enhanced emphasis on prompt and precise diagnosis, the development of personalized treatment protocols, and a move towards outpatient and at-home care models.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10676&type=smp
What Market Drivers Are Helping Shape The Non Hodgkin Lymphoma (NHL) Market Expansion?
The non-Hodgkin lymphoma market is projected to expand due to the significant occurrence of non-Hodgkin lymphoma. This form of cancer originates in the lymphatic system, a component of the body’s immune defense. Non-Hodgkin lymphoma prevalence signifies the total count of individuals within a population presently diagnosed with or affected by the condition at a given moment. Treatments for non-Hodgkin lymphoma enhance the prospects for those already diagnosed by targeting and controlling cancer cells. For example, data from January 2023 by the American Cancer Society, a US-based cancer health organization, indicates that non-Hodgkin lymphoma constitutes 4% of all cancers. In 2023, approximately 80,550 Americans are expected to be affected, comprising 44,880 males and 35,670 females. The society also forecasts 20,180 fatalities in 2023 attributed to non-Hodgkin lymphoma. Consequently, the substantial prevalence of non-Hodgkin lymphoma acts as a key driver for the non-Hodgkin lymphoma market.
What Key Segment Areas Are Included In The Non Hodgkin Lymphoma (NHL) Market Assessment?
The non hodgkin lymphoma (nhl) market covered in this report is segmented –
1) By Type: B-Cell Lymphoma, T-Cell Lymphoma
2) By Treatment: Surgery, Stem Cell Transplant, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy
3) By Route of Administration: Oral, Parenteral, Other Routes of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End Users
Subsegments:
1) By B-Cell Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphoma, Primary Mediastinal B-Cell Lymphoma
2) By T-Cell Lymphoma: Peripheral T-Cell Lymphoma (PTCL), Anaplastic Large Cell Lymphoma (ALCL), Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoblastic Lymphoma, Adult T-Cell Leukemia/Lymphoma (ATLL)
Which Trends Are Shaping The Non Hodgkin Lymphoma (NHL) Market Landscape?
Key companies operating in the non-Hodgkin lymphoma market are increasing their focus on introducing advanced immunotherapies, such as Epcoritamab-bysp (EPKINLY), to gain a competitive advantage. Epcoritamab-bysp (EPKINLY) is an investigational subcutaneous immunotherapy designed to target CD20-expressing B-cell malignancies, showing promising results in clinical trials, particularly in relapsed or refractory B-cell non-Hodgkin lymphoma. For instance, in November 2023, AbbVie Inc., a US-based pharmaceutical company, received a breakthrough therapy designation (BTD) from the United States Food and Drug Administration for Epcoritamab-bysp (EPKINLY). The approval was granted for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more therapies. Additionally, the European Medicines Agency (EMA) has validated a Type II application for epcoritamab (TEPKINLY) for the same indication. These updates were supported by previously announced results from the Phase 1/2 EPCORE NHL-1 clinical trial. The trial evaluated the safety and preliminary efficacy of subcutaneous epcoritamab in 128 adult patients with relapsed, progressive, or refractory CD20+ mature B-cell non-Hodgkin’s lymphoma (NHL), including FL.
Which Companies Form The Competitive Landscape Of The Non Hodgkin Lymphoma (NHL) Market?
Major companies operating in the non hodgkin lymphoma (nhl) market are Bayer AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann La Roche Ltd., Merck & Co. Inc., Eli Lilly and Co., Novartis AG, GlaxoSmithKline plc, AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Co., Pfizer Inc., Celgene Corporation, Sanofi S.A., Janssen Pharmaceuticals Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, Eisai Co. Ltd., Gilead Sciences, Incyte Corporation, Karyopharm Therapeutics, Kite Pharma Inc., Kyowa Hakko Kirin Co. Ltd., MorphoSys AG, Nordic Nanovector ASA, Ono Pharmaceutical Co. Ltd., Seattle Genetics Inc., Spectrum Pharmaceuticals Inc.
Access The Complete Non Hodgkin Lymphoma (NHL) Market Report:
https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report
Which Region Has The Strongest Presence In The Non Hodgkin Lymphoma (NHL) Market?
North America was the largest region in the non-Hodgkin lymphoma (NHL) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global non-Hodgkin lymphoma (NHL) market report during the forecast period. The regions covered in the non hodgkin lymphoma (nhl) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Non Hodgkin Lymphoma (NHL) Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=10676&type=smp
Browse Through More Reports Similar to the Global Non Hodgkin Lymphoma (NHL) Market 2026, By The Business Research Company
Non Hodgkin Lymphoma Nhl Market Report 2026
https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report
Non Hodgkin Lymphoma Nhl Market Report 2026
https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report
Non Hodgkin Lymphoma Nhl Market Report 2026
https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model